Philips Granted FDA Approval for COVID-19 Ultrasound Managing
Lumify is one of several Philips products recently granted FDA approval to manage COVID-19 patients. Image courtesy of Philips.

The FDA has recently granted 510(k) clearance to Philips for a range of its devices to be used to manage COVID-19 patients in the U.S. The approved products include the Affiniti series, EPIQ series, Lumify, CX50, and Sparq system.

These ultrasound devices are used to monitor and manage patients suffering from COVID-19 complications. This range of devices can be used to monitor both cardiac and respiratory complications. It can be used to measure the effects of pneumonia symptoms on peripheral lung tissue, a common symptom of severe cases of COVID-19.

The portability of these devices means that patients will be able to remain in their respective points of care, such as the intensive care unit, instead of being transferred to another area for ultrasounds. This provides patients with increased comfort, and saves time for health care providers. Additionally, reduced movement of infected patients lessens the spread of the virus throughout different areas of hospitals.

Among these recently approved products is the Lumify with Reacts, a contribution from Philips to the growing market of telehealth products. Lumify with Reacts is used to conduct ultrasound scans, but can connect to tablets or smartphones. This allows multiple parties to view the scans simultaneously and discuss the scans, which further aids efficiency and infection prevention.

Bich Le, Senior Vice President and General Manager Ultrasound at Philips, commented on the approval, stating that “With this regulatory clearance we can offer clear guidance to ensure safe and effective use of ultrasound to manage COVID-19-related lung and cardiac complications. At the same time, we are investing significantly to ramp up production globally, including at our ultrasound manufacturing plants in the US.”

Via: GlobeNewsWire

Telehealth Market

The telehealth monitoring market has grown tremendously in recent years, fueled by increasing awareness of the benefits of remote monitoring and home healthcare. Growth was heavily driven by telehealth monitoring for disease management, which represented approximately more than half of the total telehealth market value in 2018.

Currently, the U.S. boasts the most mature telehealth market in the world, as well as a diverse competitive landscape, attributable to a trend towards reimbursement reform and successes of large-scale deployment initiatives. Moreover, the Veteran’s Health Administration (VHA), America’s largest purveyor of home telehealth, continues to rapidly expand the size of its remote patient monitoring (RPM) programs and funding.

In 2018, the total market for telehealth monitoring valued at approximately $1.1 billion, a 12.6% increase over 2017, and is expected to grow at a CAGR of 11.4% by 2025.

To read more on the telehealth market, refer to iData Research’s report page: Telemedicine Market Analysis, Size, Trends | Global | 2019-2025 | MedCore

COVID-19 has already caused significant social and economic impacts on medical device organizations world-wide. At iData Research, it is our prime responsibility to keep you updated on the latest market trends in the industry. We have created a dedicated page, COVID-19: Implications for the Medical Device Industry, to post news updates and provide information on the current market situation. It is our intention that this page can help industry leaders ask the right questions, and shed light on what the future might hold for medical device markets.

Stryker Emergency Authorization for Respirator Decontamination Stryker Emergency Authorization for Respirator Decontamination